跳至主要内容
临床试验/NCT01797081
NCT01797081已完成3 期

BOTOX® in the Treatment of Crow's Feet Lines in Japan

Allergan1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2013年1月31日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
300
试验地点
1
主要终点
Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)

研究概览

简要总结

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate to severe Crow's Feet Lines

排除标准

  • Current or previous botulinum toxin treatment of any serotype
  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
  • Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months
  • Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year
  • Medium-depth or deep facial peels within 5 years
  • Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)

结局指标

主要结局

Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)

时间窗: Day 30

The Investigator assessed the severity of the patient's Crow's Feet lines at maximum smile using the 4-point Facial Wrinkle Scale where 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.

次要结局

  • Percentage of Participants Who Rate Themselves in a Younger Self-Perception of Age Category Than at Baseline(Day 30)
  • Percentage of Participants Much Improved or Very Much Improved in the Subject's Assessment of Appearance of CFL as Measured by the Global Assessment of Change in Crow's Feet Lines(Day 30)
  • Percentage of Participants Achieving a ≥1-Grade Improvement From Baseline on the Investigator's Assessment of the Severity of CFL at Rest Using the FWS-A(Day 30)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

BOTOX® in the Treatment of Crow's Feet Lines in Japan | 临床试验